Table 3. Impact of NFKB family mRNA expression levels on DRFS in patients with TNBC who received adjuvant doxorubicin chemotherapy (Cox regression).

Doxorubicin chemotherapy
Clinical variables (N = 116)	HR	95% CI	P-value
Stage			<0.001
I	1.0	NA
IIA	1.34	0.26–6.95
IIB	3.60	0.75–17.36
IIIA	7.07	1.36–36.91
IIIC	20.19	4.00–101.87
Adjuvant chemotherapy			0.664
(F)AC	1.0	NA
AC-T	0.79	0.27–2.33
NFKB1 (Median: 25.60)			0.527
Low	1.0	NA
High	0.73	0.27–1.96
RELA (Median: 224.85)			0.823
Low	1.0	NA
High	0.88	0.27–2.83
SP1 (Median: 100.01)			0.004
Low	1.0	NA
High	4.97	1.68–14.73